MIT Holding, Inc. (MITD) Prepared to Build on Prof
Post# of 36
Posted On: 09/18/2015 5:29:00 PM
MIT Holding, Inc. (MITD) Prepared to Build on Profitable Results through National Expansion Efforts
Since implementing its updated corporate goals at the beginning of 2014, MIT Holding, Inc. has made tremendous progress toward capitalizing on the steady growth of the medical industry. In the second quarter of 2015, this progress materialized into the first profitable quarter in the company’s history, as well as an 80 percent year-over-year increase in total sales. With profitability achieved, MITD is now firmly focused on promoting national expansion through both organic growth and strategic acquisitions. Through these efforts, the company will look to continue refining its first-of-its-kind, comprehensive recovery concept, which facilitates and assists patients from the time of their release from a hospital through to a full in-home recovery.
“The first six months of profit and growth validate our strategy and approach to our business model,” Walter Drakeford, chief executive officer of MITD, stated in a news release. “The unabated growth in the medical industry is creating headwinds, contributing to our continued growth and profitability.”
MITD is also benefitting from the medical industry’s ongoing shift toward value-based purchasing options. Rather than continuing to reward healthcare providers based solely on volume of care delivered, the U.S. Department of Health and Human Services (HHS) has recently pushed for a move toward less expensive, value-based care. In 2014, an estimated 20 percent of Medicare reimbursements had shifted away from volume-based payment frameworks, and HHS has set a goal to have 85 percent of Medicare fee-for-service payments in value-based purchasing categories by 2016.
As a result of this market shift, the United States home infusion market is expected to achieve steady growth moving forward, climbing at a compound annual growth rate of just over 9 percent through 2020. According to a report by Harris Williams & Co., home or alternate site home infusion services present patients with a dramatic 90 percent daily cost savings as compared to receiving the same services in a traditional hospital setting.
With its first quarter of profitability now in the books and an established expansion plan in place, MITD is in a favorable position to capitalize on the pivot toward value-based care options while continuing to promote market growth. Look for the company to lean on the marketability of its comprehensive recovery concept, as well as the strong performance of the medical industry, in order to promote sustainable returns.
For more information on MIT Holding, visit http://mitholdinginc.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Since implementing its updated corporate goals at the beginning of 2014, MIT Holding, Inc. has made tremendous progress toward capitalizing on the steady growth of the medical industry. In the second quarter of 2015, this progress materialized into the first profitable quarter in the company’s history, as well as an 80 percent year-over-year increase in total sales. With profitability achieved, MITD is now firmly focused on promoting national expansion through both organic growth and strategic acquisitions. Through these efforts, the company will look to continue refining its first-of-its-kind, comprehensive recovery concept, which facilitates and assists patients from the time of their release from a hospital through to a full in-home recovery.
“The first six months of profit and growth validate our strategy and approach to our business model,” Walter Drakeford, chief executive officer of MITD, stated in a news release. “The unabated growth in the medical industry is creating headwinds, contributing to our continued growth and profitability.”
MITD is also benefitting from the medical industry’s ongoing shift toward value-based purchasing options. Rather than continuing to reward healthcare providers based solely on volume of care delivered, the U.S. Department of Health and Human Services (HHS) has recently pushed for a move toward less expensive, value-based care. In 2014, an estimated 20 percent of Medicare reimbursements had shifted away from volume-based payment frameworks, and HHS has set a goal to have 85 percent of Medicare fee-for-service payments in value-based purchasing categories by 2016.
As a result of this market shift, the United States home infusion market is expected to achieve steady growth moving forward, climbing at a compound annual growth rate of just over 9 percent through 2020. According to a report by Harris Williams & Co., home or alternate site home infusion services present patients with a dramatic 90 percent daily cost savings as compared to receiving the same services in a traditional hospital setting.
With its first quarter of profitability now in the books and an established expansion plan in place, MITD is in a favorable position to capitalize on the pivot toward value-based care options while continuing to promote market growth. Look for the company to lean on the marketability of its comprehensive recovery concept, as well as the strong performance of the medical industry, in order to promote sustainable returns.
For more information on MIT Holding, visit http://mitholdinginc.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)MIT Holding, Inc. (MITD) Stock Research Links
Scroll down for more posts ▼